

13710 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

as well as public interest in today's hearing will bring the new labeling to the attention of physicians and help begin to persuade them that the UGDP findings should change the way they treat diabetic patients. In addition, the FDA plans to issue a Drug Bulletin when the labeling for these drugs is made final. We will monitor the use of these drugs and will take additional measures as necessary to publicize the final labeling.

I will be pleased, Mr. Chairman, to answer any questions.